Neuroimmunology Drugs Market
完整報告名稱與涵蓋範圍
Neuroimmunology Drugs Market Size, Share & Trends Analysis Distribution by Disease Focus (Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Autoimmune Encephalitis, Other Rare Neuroimmune Disorders), Therapeutic Approach, Mechanism of Action, Development Stage, Delivery Method, CNS-Targeted, Biomarker Integration and Segment Forecasts, 2025-2034
報告摘要
Across the 2025 to 2034 projection horizon, the worldwide Neuroimmunology Drugs Market is forecasted to register a CAGR of 9.7%.
Neuroimmunology Drugs encompasses The Neuroimmunology Drugs Market is growing very fast, driven by expanding knowledge of the complex interaction between the immune and nervous systems. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
The market's upward path is bolstered by expanding healthcare spending, technological evolution, and the expanding focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region forecasted to deliver the strongest growth trajectory through the forecast period, bolstered by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neuroimmunology Drugs Market Snapshot
Chapter 4. Global Neuroimmunology Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Global Neuroimmunology Drugs Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Radiopharma Industry Trends
Chapter 5. Neuroimmunology Drugs Market Segmentation 1: By Disease Focus, Estimates & Trend Analysis
5.1. Market Share by Disease Focus, 2023 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Disease Focus:
5.2.1. Multiple Sclerosis (MS)
5.2.2. Neuromyelitis Optica Spectrum Disorder (NMOSD)
5.2.3. Alzheimer's Disease (AD)
5.2.4. Parkinson's Disease (PD)
5.2.5. Amyotrophic Lateral Sclerosis (ALS)
5.2.6. Autoimmune Encephalitis
5.2.7. Other Rare Neuroimmune Disorders
Chapter 6. Neuroimmunology Drugs Market Segmentation 2: By Therapeutic Approach, Estimates & Trend Analysis
6.1. Market Share by Therapeutic Approach, 2023 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Therapeutic Approach:
6.2.1. Monoclonal Antibodies
6.2.2. Bruton's Tyrosine Kinase Inhibitors (BTKIs)
6.2.3. CAR-T Cell Therapies
6.2.4. Small Molecules
6.2.5. Microglia-Targeted Therapies
6.2.6. Gene and Stem Cell Therapies
Chapter 7. Neuroimmunology Drugs Market Segmentation 3: By Mechanism of Action, Estimates & Trend Analysis
7.1. Market Share by Mechanism of Action 2023 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Mechanism of Action:
7.2.1. Immune Cell Depletion
7.2.2. Immune Cell Trafficking Inhibition
7.2.3. Cytokine Modulation
7.2.4. Microglial Regulation
7.2.5. Complement Inhibition
7.2.6. Remyelination and Neuroprotection
Chapter 8. Neuroimmunology Drugs Market Segmentation 4: By Development Stage, Estimates & Trend Analysis
8.1. Market Share by Development Stage, 2023 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Development Stage:
8.2.1. Approved Therapies
8.2.2. Clinical Pipeline (Phase I–III)
8.2.3. Preclinical Innovations
Chapter 9. Neuroimmunology Drugs Market Segmentation 5: By Delivery Method, Estimates & Trend Analysis
9.1. Market Share by Delivery Method, 2023 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Delivery Method:
9.2.1. Systemic (IV, Subcutaneous, Oral)
9.2.2. CNS-Targeted (Intranasal, Intrathecal, Nanoparticle-Based)
9.2.3. Cell-Based
Chapter 10. Neuroimmunology Drugs Market Segmentation 6: By Biomarker Integration, Estimates & Trend Analysis
10.1. Market Share by Biomarker Integration, 2023 & 2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Biomarker Integration:
10.2.1. Diagnostic Biomarkers
10.2.2. Predictive Biomarkers
10.2.3. Monitoring Biomarkers
Chapter 11. Neuroimmunology Drugs Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. Global Neuroimmunology Drugs Market, Regional Snapshot 2023 & 2034
11.2. North America
11.2.1. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.2.1.1. US
11.2.1.2. Canada
11.2.2. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease Focus, 2021-2034
11.2.3. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Approach, 2021-2034
11.2.4. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action 2021-2034
11.2.5. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Development Stage, 2021-2034
11.2.6. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
11.2.7. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Integration, 2021-2034
11.3. Europe
11.3.1. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.3.1.1. Denmark
11.3.1.2. Finland
11.3.1.3. Austria
11.3.1.4. France
11.3.1.5. Germany
11.3.1.6. Israel
11.3.1.7. Italy
11.3.1.8. Netherlands
11.3.1.9. Norway
11.3.1.10. Poland
11.3.2. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease Focus, 2021-2034
11.3.3. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Approach, 2021-2034
11.3.4. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action 2021-2034
11.3.5. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Development Stage, 2021-2034
11.3.6. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
11.3.7. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Integration, 2021-2034
11.4. Asia Pacific
11.4.1. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.4.1.1. Australia
11.4.1.2. China
11.4.1.3. India
11.4.1.4. Indonesia
11.4.1.5. Japan
11.4.1.6. Malaysia
11.4.1.7. Philippines
11.4.1.8. Singapore
11.4.1.9. South Korea
11.4.1.10. Taiwan
11.4.1.11. Thailand
11.4.1.12. Rest of APAC
11.4.2. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease Focus, 2021-2034
11.4.3. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Approach, 2021-2034
11.4.4. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts By Mechanism of Action 2021-2034
11.4.5. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Development Stage, 2021-2034
11.4.6. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
11.4.7. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Integration, 2021-2034
11.5. Latin America
11.5.1. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.5.1.1. Argentina
11.5.1.2. Brazil
11.5.1.3. Mexico
11.5.1.4. Rest of LATAM
11.5.2. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease Focus, 2021-2034
11.5.3. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Approach, 2021-2034
11.5.4. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action 2021-2034
11.5.5. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Development Stage, 2021-2034
11.5.6. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
11.5.7. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Integration, 2021-2034
11.6. Middle East & Africa
11.6.1. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
11.6.1.1. Egypt
11.6.1.2. Israel
11.6.1.3. Nigeria
11.6.1.4. Saudi Arabia
11.6.1.5. Qatar
11.6.1.6. United Arab Emirates
11.6.1.7. Rest of MEA
11.6.2. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease Focus, 2021-2034
11.6.3. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Approach, 2021-2034
11.6.4. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action 2021-2034
11.6.5. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Development Stage, 2021-2034
11.6.6. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
11.6.7. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Integration, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Roche
12.2.1.1. Business Overview
12.2.1.2. Key Product/Service
12.2.1.3. Financial Performance
12.2.1.4. Modeance
12.2.1.5. Geographical Presence
12.2.1.6. Recent Developments with Business Strategy
12.2.2. Biogen
12.2.3. Sanofi
12.2.4. Novartis
12.2.5. Merck KGaA
12.2.6. Bristol Myers Squibb
12.2.7. AstraZeneca (Alexion)
12.2.8. Eli Lilly
12.2.9. UCB
12.2.10. Kyverna Therapeutics
12.2.11. Abata Therapeutics
12.2.12. Vigil Neuroscience
12.2.13. Denali Therapeutics
12.2.14. Takeda
12.2.15. Amgen
12.2.16. GSK
12.2.17. Sarepta Therapeutics
12.2.18. Neurona Therapeutics
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們